✦ LIBER ✦

Therapy-related myelodysplastic syndrome or acute myelogenous leukemia in patients with acute promyelocytic leukemia (APL)

✍ Scribed by Garcia-Manero, G; Kantarjian, H M; Kornblau, S; Estey, E

Book ID: 110055174
Publisher: Nature Publishing Group
Year: 2002
Tongue: English
Weight: 67 KB
Volume: 16
Category: Article
ISSN: 0887-6924
DOI: 10.1038/sj.leu.2402616

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Therapy-related acute myelogenous leukem

✍ Gautam Borthakur; Elihu E. Estey 📂 Article 📅 2007 🏛 Current Science Inc. 🌐 English ⚖ 216 KB

Therapy-related acute myelogenous leukem

✍ Dushyant Verma; Susan O'Brien; Deborah Thomas; Stefan Faderl; Charles Koller; Sh 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 114 KB 👁 1 views

## Abstract ## BACKGROUND: Secondary malignancies including myeloid neoplasms occur infrequently in acute lymphoblastic leukemia (ALL) and to the authors' knowledge have not been as well documented in adults as in children. ## METHODS: A total of 641 patients with de novo ALL who were treated wi

Cognitive impairment, fatigue, and cytok

Cognitive impairment, fatigue, and cytokine levels in patients with acute myelogenous leukemia or myelodysplastic syndrome

✍ Christina A. Meyers; Maher Albitar; Elihu Estey 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 105 KB 👁 1 views

Predictors and outcome of acute kidney i

Predictors and outcome of acute kidney injury in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome

✍ Amit Lahoti; Hagop Kantarjian; Abdulla K. Salahudeen; Farhad Ravandi; Jorge E. C 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 185 KB 👁 1 views

Association of anemia and cognitive dysf

Association of anemia and cognitive dysfunction in patients with acute myelogenous leukemia and myelodysplastic syndrome

✍ Susan M. Wood; Christina A. Meyers; Stefan Faderl; Hagop M. Kantarjian; Sherry A 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 324 KB 👁 3 views

Gemtuzumab, fludarabine, cytarabine, and

Gemtuzumab, fludarabine, cytarabine, and cyclosporine in patients with newly diagnosed acute myelogenous leukemia or high-risk myelodysplastic syndromes

✍ Apostolia Tsimberidou; Elihu Estey; Jorge Cortes; Deborah Thomas; Stefan Faderl; 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 90 KB 👁 1 views

## Background: Gemtuzumab is used to treat patients with previously untreated or recurrent acute myelogenous leukemia (aml). the fludarabine and cytarabine (ara-c) regimen is active in these patients. resistance to gemtuzumab is associated with blast multidrug resistance (mdr). the objectives of th